Please login to the form below

Not currently logged in
Email:
Password:

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq misses survival mark in frontline NSCLC

Roche’s Tecentriq misses survival mark in frontline NSCLC

Roche's hopes of challenging Merck &Co for a slice of the lucrative first-line non-small cell lung cancer (NSCLC) immunotherapy market have been set back after a missed trial ... This is our third phase 3 trial in non-squamous non-small cell lung cancer

Latest news

  • China’s BeiGene raises $903m from Hong Kong IPO China’s BeiGene raises $903m from Hong Kong IPO

    The company – which has just started pivotal trials for its lead cancer immunotherapy tislelizumab and hopes to file it in China this year – is the ninth biotech to take advantage of ... cancer (NSCLC), hepatocellular carcinoma, and oesophageal

  • CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

    The new Keytruda indications were for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations ... in combination with chemotherapy, and as a second-line

  • Bluebird and Celgene BCMA CAR-T kicks off ASCO Bluebird and Celgene BCMA CAR-T kicks off ASCO

    Bluebird and Celgene BCMA CAR-T kicks off ASCO. Will be reporting updated phase I trial data for bb2121in patients with bone marrow cancer. ... option for patients with metastatic squamous non-small cell lung cancer (NSCLC) - regardless of PD-L1

  • Daily Brief: AstraZeneca's new San Fran hoKeytruda triumphs again, Novo branches out

    Topline data from its Keynote 407 study of the drug as a first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC), met the dual primary endpoints of improved ... Previously untreated patients with the squamous NSCLC, represent

  • Roche eyes September FDA verdict for triple NSCLC therapy Roche eyes September FDA verdict for triple NSCLC therapy

    The FDA has started a six-month review of Roche’s Tecentriq, Avastin and chemotherapy in first-line non-small cell lung cancer, setting up a possible approval by 5 September. ... Roche is pairing Tecentriq and Avastin in multiple cancer indications,

More from news
Approximately 0 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics